Saranraj Kamaraj MBBS MDAmit Agrawal Amit Korgaonkar Dr Arpit Jain Santosh Jagtap To view or add a comment, sign in Emerging evidence shows that when people stop taking GLP-1 weight-loss drugs, weight often returns and cardiometabolic risks may resurface, highlighting the importance of long-term strategies that pair medication with sustainable lifestyle and care support
While it varies from person to person, the first sign of perimenopause is often irregular periods
Drug Makers Ignore More Significant Evidence in Trials The International Journal of Clinical Pharmacy highlighted a concerning association between semaglutide and adverse psychiatric events. Between January 2021 and May 2023, databases recorded 481 psychiatric events associated with GLP-1 medications and similar drugs, including 9 deaths and 11 life-threatening outcomes. Poison control centers reported nearly 3,000 calls involving semaglutide in less than a year
Such assemblies exhibit strong steric constraints and, therefore, can sustain a lot of moisture (Ling et al., 2015)
Wei P, He M, Wang Y, Han G
Angiogenesis in Breast Cancer Progression, Diagnosis, and Treatment
